|
1
|
Patel SH, Poisson LM, Brat DJ, Zhou Y,
Cooper L, Snuderl M, Thomas C, Franceschi AM, Griffith B, Flanders
AE, et al: T2-FLAIR mismatch, an imaging biomarker for IDH and
1p/19q status in lower-grade gliomas: A TCGA/TCIA project. Clin
Cancer Res. 23:6078–6085. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jooma R, Waqas M and Khan I: Diffuse
Low-grade glioma-changing concepts in diagnosis and management: A
review. Asian J Neurosurg. 14:356–363. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nahed BV, Redjal N, Brat DJ, Chi AS, Oh K,
Batchelor TT, Ryken TC, Kalkanis SN and Olson JJ: Management of
patients with recurrence of diffuse low grade glioma: A systematic
review and evidence-based clinical practice guideline. J
Neurooncol. 125:609–630. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fournier C, Mercey-Ressejac M, Derangère
V, Al Kadi A, Rageot D, Charrat C, Leroy A, Vollaire J, Josserand
V, Escudé M, et al: Nanostructured lipid carriers based mRNA
vaccine leads to a T cell-inflamed tumour microenvironment
favourable for improving PD-1/PD-L1 blocking therapy and long-term
immunity in a cold tumour model. EBioMedicine. 112:1055432025.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun X, Jia Q, Li K, Tian C, Yi L, Yan L,
Zheng J, Jia X and Gu M: Comparative genomic landscape of
lower-grade glioma and glioblastoma. PLoS One. 19:e03095362024.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang YS, Liu MH, Yan ZW, Chen GQ and Huang
Y: FAM122A is required for mesendodermal and cardiac
differentiation of embryonic stem cells. Stem Cells. 41:354–367.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fan F, Zhao J, Liu Y, Zhao H, Weng L, Li
Q, Chen G and Xu Y: Identifying the SUMO1 modification of FAM122A
leading to the degradation of PP2A-Cα by ubiquitin-proteasome
system. Biochem Biophys Res Commun. 500:676–681. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wasserman JS, Faezov B, Patel KR,
Kurimchak AM, Palacio SM, Glass DJ, Fowle H, McEwan BC, Xu Q, Zhao
Z, et al: FAM122A ensures cell cycle interphase progression and
checkpoint control by inhibiting B55α/PP2A through helical motifs.
Nat Commun. 15:57762024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu MH, Chen J, Yang YS, Wang YQ, Chen GQ,
Zhang Y and Huang Y: FAM122A promotes acute myeloid leukemia cell
growth through inhibiting PP2A activity and sustaining MYC
expression. Haematologica. 106:903–907. 2021.PubMed/NCBI
|
|
11
|
Zhou Y, Shi WY, He W, Yan ZW, Liu MH, Chen
J, Yang YS, Wang YQ, Chen GQ and Huang Y: FAM122A supports the
growth of hepatocellular carcinoma cells and its deletion enhances
Doxorubicin-induced cytotoxicity. Exp Cell Res. 387:1117142020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kawaguchi A, Yajima N, Tsuchiya N, Homma
J, Sano M, Natsumeda M, Takahashi H, Fujii Y, Kakuma T and Yamanaka
R: Gene expression signature-based prognostic risk score in
patients with glioblastoma. Cancer Sci. 104:1205–1210. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Buczkowicz P, Hoeman C, Rakopoulos P,
Pajovic S, Letourneau L, Dzamba M, Morrison A, Lewis P, Bouffet E,
Bartels U, et al: Genomic analysis of diffuse intrinsic pontine
gliomas identifies three molecular subgroups and recurrent
activating ACVR1 mutations. Nat Genet. 46:451–456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu X, Feng L, Liu D, Zhang L, Wu B, Jiang
W, Han Z and Cheng S: Quantitative proteomics reveals the novel
co-expression signatures in early brain development for prognosis
of glioblastoma multiforme. Oncotarget. 7:14161–14171. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feng L, Qian H, Yu X, Liu K, Xiao T, Zhang
C, Kuang M, Cheng S, Li X, Wan J and Zhang K: Heterogeneity of
tumor-infiltrating lymphocytes ascribed to local immune status
rather than neoantigens by multi-omics analysis of glioblastoma
multiforme. Sci Rep. 7:69682017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park CK, Park I, Lee S, Sun CH, Koh Y,
Park SH, Kim JE, Yun H and Lee SH: Genomic dynamics associated with
malignant transformation in IDH1 mutated gliomas. Oncotarget.
6:43653–43666. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Björkblom B, Wibom C, Eriksson M,
Bergenheim AT, Sjöberg RL, Jonsson P, Brännström T, Antti H,
Sandström M and Melin B: Distinct metabolic hallmarks of WHO
classified adult glioma subtypes. Neuro Oncol. 24:1454–1468. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen W, Lei C, Liu P, Liu Y, Guo X, Kong Z
and Wang Y, Dai C and Wang Y, Ma W and Wang Y: Progress and
prospects of recurrent glioma: A recent scientometric analysis of
the web of science in 2019. World Neurosurg. 134:e387–e399. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Decuyper M, Bonte S, Deblaere K and Van
Holen R: Automated MRI based pipeline for segmentation and
prediction of grade, IDH mutation and 1p19q co-deletion in glioma.
Comput Med Imaging Graph. 88:1018312021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang S, Ernberg I and Kauffman S: Cancer
attractors: A systems view of tumors from a gene network dynamics
and developmental perspective. Semin Cell Dev Biol. 20:869–876.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tao H, Liao Y, Yan Y, He Z, Zhou J, Wang
X, Peng J, Li S and Liu T: BRCC3 promotes tumorigenesis of bladder
cancer by activating the NF-κB signaling pathway through targeting
TRAF2. Front Cell Dev Biol. 9:7203492021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han X, Wang Z, Zhang L, Shen Y, Tan Q, Sun
Y, Wang J, Qian X, Yang H and Shi Y: SLF1 polymorphism predicts
response to oxaliplatin-based adjuvant chemotherapy in patients
with colon cancer. Am J Cancer Res. 11:1522–1539. 2021.PubMed/NCBI
|
|
24
|
Zhang H, Xiao X, Wei W, Huang C, Wang M,
Wang L, He Y, Sun J, Jiang Y, Jiang G and Zhang X: CircLIFR
synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73
axis in bladder cancer. Mol Cancer. 20:702021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu B, Huang X, Shi X, Jiang M, Liu H and
Zhao L: LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy
efficacy in non-small cell lung cancer. Mol Cancer. 23:1842024.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mohammed HN, Pickard MR and
Mourtada-Maarabouni M: The protein phosphatase 4-PEA15 axis
regulates the survival of breast cancer cells. Cell Signal.
28:1389–1400. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Neophytou CM, Panagi M, Stylianopoulos T
and Papageorgis P: The role of tumor microenvironment in cancer
metastasis: Molecular mechanisms and therapeutic opportunities.
Cancers. 13:20532021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang P, Cao X, Guan M, Li D, Xiang H,
Peng Q, Zhou Y, Weng C, Fang X, Liu X, et al: CPNE8 promotes
gastric cancer metastasis by modulating focal adhesion pathway and
tumor microenvironment. Int J Biol Sci. 18:4932–4949. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Benencia F, Alaniz LD and McCall KD:
Editorial: Toll-like receptor expression in transformed cells: Role
in tumor development and cancer therapies. Front Immunol.
15:14784312024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mortezaee K: Immune escape: A critical
hallmark in solid tumors. Life Sci. 258:1181102020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ostrom QT, Price M, Neff C, Cioffi G,
Waite KA, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the United States in 2015–2019. Neuro Oncol. 24 (Suppl
5):v1–v95. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakasu S and Nakasu Y: Malignant
progression of diffuse Low-grade Gliomas: A systematic review and
Meta-analysis on incidence and related factors. Neurol Med Chir
(Tokyo). 62:177–185. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang YQ, Yang YS, Chen J, Liu MH, Chen GQ
and Huang Y: FAM122A maintains DNA stability possibly through the
regulation of topoisomerase IIα expression. Exp Cell Res.
396:1122422020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Familiari P, Lapolla P, Picotti V,
Palmieri M, Pesce A, Carosi G, Relucenti M, Nottola S, Gianno F,
Minasi S, et al: Role of 1p/19q codeletion in diffuse Low-grade
glioma tumour prognosis. Anticancer Res. 43:2659–2670. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Talari K and Goyal M: Retrospective
studies-utility and caveats. J R Coll Physicians Edinb. 50:398–402.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Charmpi K, Guo T, Zhong Q, Wagner U, Sun
R, Toussaint NC, Fritz CE, Yuan C, Chen H, Rupp NJ, et al:
Convergent network effects along the axis of gene expression during
prostate cancer progression. Genome Biol. 21:3022020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang Q, Zheng S, Gu H, Yang Z, Lu Y, Yu X
and Guo G: The deubiquitinase BRCC3 increases the stability of ZEB1
and promotes the proliferation and metastasis of triple-negative
breast cancer cells. Acta Biochim Biophys Sin (Shanghai).
56:564–575. 2024.PubMed/NCBI
|
|
39
|
Zhang F and Zhou Q: Knockdown of BRCC3
exerts an anti-tumor effect on cervical cancer in vitro. Mol
Med Rep. 18:4886–4894. 2018.PubMed/NCBI
|
|
40
|
Hu X, Wu J and Xu J: UCA1 executes an
oncogenic role in pancreatic cancer by regulating miR-582-5p/BRCC3.
Front Oncol. 13:11332002023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Feng X, He S, Chen Y and Zhang L:
Deubiquitinase BRCC3 promotes the migration, invasion and EMT
progression of colon adenocarcinoma by stabilizing MET expression.
Genes Genomics. 46:637–646. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ko JC, Chiu HC, Wo TY, Huang YJ, Tseng SC,
Huang YC, Chen HJ, Syu JJ, Chen CY, Jian YT, et al: Inhibition of
p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin
enhances gefitinib-induced cytotoxicity in human squamous lung
cancer cells. Lung Cancer. 82:397–406. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sun Y, Guan Z, Sheng Q, Duan W, Zhao H,
Zhou J, Deng Q and Pei X: N-myristoyltransferase-1 deficiency
blocks myristoylation of LAMTOR1 and inhibits bladder cancer
progression. Cancer Lett. 529:126–138. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao L, Gao N, Peng X, Chen L, Meng T,
Jiang C, Jin J, Zhang J, Duan Q, Tian H, et al: TRAF4-mediated
LAMTOR1 ubiquitination promotes mTORC1 activation and inhibits the
inflammation-induced colorectal cancer progression. Adv Sci
(Weinh). 11:e23011642024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kidd LC, Rogers EN, Yeyeodu ST, Jones DZ
and Kimbro KS: Contribution of toll-like receptor signaling
pathways to breast tumorigenesis and treatment. Br Cancer (Dove Med
Press). 5:43–51. 2013.PubMed/NCBI
|
|
46
|
Liu Z, Zhang X, Ben T, Li M, Jin Y, Wang T
and Song Y: Focal adhesion in the tumour metastasis: From molecular
mechanisms to therapeutic targets. Biomark Res. 13:382025.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lu P, Weaver VM and Werb Z: The
extracellular matrix: A dynamic niche in cancer progression. J Cell
Biol. 196:395–406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cui X, Morales RT, Qian W, Wang H, Gagner
JP, Dolgalev I, Placantonakis D, Zagzag D, Cimmino L, Snuderl M, et
al: Hacking macrophage-associated immunosuppression for regulating
glioblastoma angiogenesis. Biomaterials. 161:164–178. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xiong J, Xiao R, Zhao J, Zhao Q, Luo M, Li
F, Zhang W and Wu M: Matrix stiffness affects tumor-associated
macrophage functional polarization and its potential in tumor
therapy. J Transl Med. 22:852024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ellert-Miklaszewska A, Poleszak K,
Pasierbinska M and Kaminska B: Integrin signaling in glioma
pathogenesis: From biology to therapy. Int J Mol Sci. 21:8882020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Norollahi SE, Babaei K, Rashidy-Pour A,
Yousefi B, Baharlou R, Far BF, Jalali A and Samadani AA: Role of
the TLR signaling pathway in the pathogenesis of glioblastoma
multiforme with an emphasis on immunotherapy. Biochem Biophys Rep.
43:1021492025.PubMed/NCBI
|
|
52
|
Wiemer AJ, Wernimont SA, Cung TD, Bennin
DA, Beggs HE and Huttenlocher A: The focal adhesion kinase
inhibitor PF-562,271 impairs primary CD4+ T cell activation.
Biochem Pharmacol. 86:770–781. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Guo M, Liu MYR and Brooks DG: Regulation
and impact of tumor-specific CD4(+) T cells in cancer and
immunotherapy. Trends Immunol. 45:303–313. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Accogli T, Bruchard M and Végran F:
Modulation of CD4 T cell response according to tumor cytokine
microenvironment. Cancers. 13:3732021. View Article : Google Scholar : PubMed/NCBI
|
